CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive: We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents.